NEUP

Neuphoria Therapeutics Inc. (NASDAQ:NEUP) is a clinical-stage biotechnology company founded on December 23, 2024, and headquartered in Burlington, Massachusetts. The company went public on December 16, 2021, and focuses on developing innovative therapies for individuals affected by neuropsychiatric disorders. As a relatively new entrant in the biotechnology sector, Neuphoria represents the emerging wave of specialized pharmaceutical companies targeting the complex intersection of neurology and psychiatry, an area that has historically been underserved by traditional drug development approaches.